Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17082012 | 1.00 | CRBN (0.42) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL4570061 | 0.94 | SMN1; SMN2 (0.43) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL17082010 | 0.94 | SMN1; SMN2 (0.43) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL4570143 | 0.92 | CRBN (0.45) | CRBNDGAT1MAPTALDH1A1LMNA | |
| SCHEMBL17082009 | 0.92 | CRBN (0.45) | CRBNDGAT1MAPTALDH1A1LMNA | |
| SCHEMBL4570059 | 0.92 | CRBN (0.44) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL17082068 | 0.92 | CRBN (0.44) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL17082006 | 0.91 | CRBN (0.41) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL4570063 | 0.91 | CRBN (0.41) | CRBNDGAT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL2697801 | 0.89 | CRBN (0.44) | CRBNDGAT1CYP1A2MAPTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CRBN 2898/4885DGAT1 2016/4885CYP1A2 134/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CRBN 2898/4885DGAT1 2016/4885CYP1A2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.